[Postexposure prevention after occupational exposure to HBV, HCV and HIV].
Sarrazin
U
U
Brodt
R
R
Sarrazin
C
C
Zeuzem
S
S
D000208:Acute Disease; D019380:Anti-HIV Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D015658:HIV Infections / Q000175:diagnosis / Q000517:prevention & control* / Q000635:transmission; D006509:Hepatitis B / Q000175:diagnosis / Q000517:prevention & control* / Q000635:transmission; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006526:Hepatitis C / Q000175:diagnosis / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007116:Immunization, Passive; D007117:Immunization, Secondary; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000517:prevention & control*; D016898:Interferon-alpha / Q000008:administration & dosage; D009784:Occupational Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012307:Risk Factors
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D016898:Interferon-alpha